[go: up one dir, main page]

PT832264E - Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao. - Google Patents

Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao.

Info

Publication number
PT832264E
PT832264E PT96914556T PT96914556T PT832264E PT 832264 E PT832264 E PT 832264E PT 96914556 T PT96914556 T PT 96914556T PT 96914556 T PT96914556 T PT 96914556T PT 832264 E PT832264 E PT 832264E
Authority
PT
Portugal
Prior art keywords
plasmid
cells
nucleic acids
plasmide
transfer
Prior art date
Application number
PT96914556T
Other languages
English (en)
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Publication of PT832264E publication Critical patent/PT832264E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96914556T 1995-06-07 1996-04-23 Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao. PT832264E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/484,723 US5763270A (en) 1995-06-07 1995-06-07 Plasmid for delivery of nucleic acids to cells and methods of use

Publications (1)

Publication Number Publication Date
PT832264E true PT832264E (pt) 2006-10-31

Family

ID=23925336

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96914556T PT832264E (pt) 1995-06-07 1996-04-23 Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao.

Country Status (9)

Country Link
US (2) US5763270A (pt)
EP (1) EP0832264B1 (pt)
JP (1) JP4335309B2 (pt)
AT (1) ATE323169T1 (pt)
AU (1) AU711187B2 (pt)
CA (1) CA2222601C (pt)
DE (1) DE69636032T2 (pt)
PT (1) PT832264E (pt)
WO (1) WO1996040952A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization
US6743780B1 (en) 1995-09-08 2004-06-01 Cobra Biologics Limited Plasmid stabilization
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
WO1999014313A2 (en) * 1997-09-19 1999-03-25 Metabolix, Inc. Biological systems for manufacture of polyhydroxylalkanoate polymers containing 4-hydroxyacids
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
PL349041A1 (en) * 1998-12-02 2002-07-01 Univ Maryland Plasmid maintenance system for antigen delivery
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US20040259252A1 (en) * 2001-07-18 2004-12-23 Sanders Mitchell C. Vector containing an enhanced p15a origin of replication
US20040235121A1 (en) * 2002-08-29 2004-11-25 Integrigen, Inc. High copy number plasmids and their derivatives
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006078979A2 (en) * 2005-01-20 2006-07-27 Nature Technology Corp. Vectors and methods for genetic immunization
MX2007010306A (es) * 2005-02-23 2007-09-26 Uab Research Foundation Vacunacion mejorada con alquil-glicosido.
WO2006099574A2 (en) * 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
EP1885863B1 (en) 2005-05-31 2014-11-19 The Regents of the University of Colorado, a body corporate Methods for delivering genes
JP4528972B2 (ja) * 2005-07-11 2010-08-25 国立大学法人鳥取大学 染色体組み込みマンノース発酵性ザイモモナス属細菌
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
MX2009008413A (es) * 2007-02-06 2009-11-02 Tai June Yoo Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
AU2012272908A1 (en) 2011-06-21 2013-12-19 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
DK2951290T3 (en) 2013-02-01 2018-01-22 Us Health PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)
ES2825078T3 (es) 2013-03-15 2021-05-14 Univ Loma Linda Tratamiento de enfermedades autoinmunitarias
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
SG11201606101WA (en) 2014-02-06 2016-08-30 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
DK3347456T3 (da) 2015-09-08 2024-02-19 Us Health Fremgangsmåde til reproducerbar differentiering af retinale pigmentepitelceller af klinisk kvalitet
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
EP3491134B1 (en) 2016-08-01 2023-10-11 University of Pittsburgh - of The Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
WO2018089515A1 (en) 2016-11-09 2018-05-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3d vascularized human ocular tissue for cell therapy and drug discovery
WO2018152120A1 (en) 2017-02-14 2018-08-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
MX2019011897A (es) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Celulas efectoras inmunitarias especificas de antigenos.
CA3097428A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP7604370B2 (ja) 2018-11-19 2024-12-23 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 生分解性組織置換インプラントおよびその使用
KR20210096638A (ko) 2018-11-28 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
EP4471129A3 (en) 2018-11-29 2025-02-19 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2021243203A1 (en) 2020-05-29 2021-12-02 FUJIFILM Cellular Dynamics, Inc. Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
AU2021280343A1 (en) 2020-05-29 2022-12-08 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
CN117881777A (zh) 2021-05-26 2024-04-12 富士胶片细胞动力公司 防止多能干细胞中基因快速沉默的方法
WO2022251477A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
CA3220602A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
US20230078230A1 (en) 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
KR20250038661A (ko) 2022-06-29 2025-03-19 후지필름 홀딩스 아메리카 코포레이션 Ipsc-유래된 성상 세포 및 이의 사용 방법
JP2025532957A (ja) 2022-09-30 2025-10-03 フジフィルム セルラー ダイナミクス，インコーポレイテッド 心臓線維芽細胞の作製方法
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019506A (en) * 1986-05-21 1991-05-28 University College, Cork Plasmid and uses thereof
HU197595B (en) * 1987-09-16 1989-04-28 Richter Gedeon Vegyeszet Process for producing expression vectors
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5492890A (en) * 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
US5308760A (en) * 1992-01-10 1994-05-03 Washington Research Foundation Crystal proteins of Bacillus thuringiensis, genes encoding them, and host expressing them
GB9312070D0 (en) * 1993-06-11 1993-07-28 Thrombosis Res Inst Untranslated exon-1 sequences of eukaryotic genes as promoters
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization

Also Published As

Publication number Publication date
DE69636032D1 (de) 2006-05-24
JP4335309B2 (ja) 2009-09-30
CA2222601A1 (en) 1996-12-19
EP0832264B1 (en) 2006-04-12
US5763270A (en) 1998-06-09
ATE323169T1 (de) 2006-04-15
CA2222601C (en) 2012-07-10
DE69636032T2 (de) 2006-11-23
JPH11511009A (ja) 1999-09-28
US6103470A (en) 2000-08-15
AU5788096A (en) 1996-12-30
EP0832264A1 (en) 1998-04-01
WO1996040952A1 (en) 1996-12-19
AU711187B2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
PT832264E (pt) Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao.
ATE290403T1 (de) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
DE69831417D1 (de) Duale selektionkassette und sie enthaltende plasmide
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
ATE301201T1 (de) Für die gentherapie verwendbare plasmide
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
HUP0004589A1 (hu) Javított eljárás nukleinsav bevitelére harántcsikolt izomba és kombinált alkalmazása
AU4882296A (en) DNA molecules, preparation and use in gene therapy
WO1995024485A3 (en) Coordinate in vivo gene expression
DE69434486D1 (de) Adenovirus vektoren für gentherapie
NZ289720A (en) Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
MX9800719A (es) Proteinas de transporte y sus usos.
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
AU6953896A (en) Inverted chimeric and hybrid oligonucleotides
WO1998034952A3 (en) Il-2 gene expression and delivery systems and uses
AU682140B2 (en) Multidrug resistance gene
GB9930418D0 (en) Replication incompetent herpes virus vectors
IL181695A0 (en) Methods for cultivating cells and propagating viruses
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
AU3919997A (en) Nucleic acid constructs containing hybrid promoters for use in gene therapy
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
DK0843731T3 (da) Adenovirusvektorer til genterapi
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon